The genetic aspects of nicotine metabolism and their impact on adolescent nicotine dependence

Journal of Pediatric Biochemistry

Volumn 1, Issue 2, 2010, Pages 105-123

  Koudsi, Nael Al ^a   O'Loughlin, Jennifer ^b   Rodriguez, Daniel ^c   Audrain McGovern, Janet ^c   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adolescent; CYP2A6; nicotine; pharmacogenetics; smoking

Indexed keywords

ALDEHYDE OXIDASE; CYTOCHROME P450; CYTOCHROME P450 2A6; DIMETHYLANILINE MONOOXYGENASE; GLUCURONOSYLTRANSFERASE; NICOTINE;

ADOLESCENCE; AGE; AOX1 GENE; ARTICLE; CHILD BEHAVIOR; CIGARETTE SMOKING; CYP2A6 GENE; CYP2B6 GENE; FMO3 GENE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SMOKING CESSATION; TOBACCO DEPENDENCE; TOXICOKINETICS; UGT2B10 GENE;

EID: 79959313939     PISSN: 18795390     EISSN: 18795404     Source Type: Journal    
DOI: 10.3233/JPB-2010-0014     Document Type: Article

References (129)

1. J.E. Henningfield, K. Miyasato and D.R. Jasinski, Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine, J Pharmacol Exp Ther 234 (1985), 1-12. (Pubitemid 15034883)
2. M.A.Russell, Nicotine intake and its regulation, JPsychosom Res 24 (1980), 253-264.
3. N.L. Benowitz and P. Jacob, 3rd. Nicotine renal excretion rate influences nicotine intake during cigarette smoking, J Pharmacol Exp Ther 234 (1985), 153-155. (Pubitemid 15034904)
4. N.L. Benowitz and P. Jacob, 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method, Clin Pharmacol Ther 56 (1994), 483-493. (Pubitemid 24370355)
5. J.Hukkanen and P. Jacob, 3rd, BenowitzNL.Metabolismand disposition kinetics of nicotine, Pharmacol Rev 57 (2005), 79-115.
6. J. O'Loughlin, G. Paradis, W. Kim et al., Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers, Tob Control 13 (2004), 422-428. (Pubitemid 39635932)
7. K.A. Schoedel, E.B. Hoffmann, Y. Rao, E.M. Sellers and R.F. Tyndale, Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians, Pharmacogenetics 14 (2004), 615-626. (Pubitemid 39281816)
8. V. Malaiyandi, C. Lerman, N.L. Benowitz, C. Jepson, F. Patterson and R.F. Tyndale, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy, Mol Psychiatry 11 (2006), 400-409.
9. N. Minematsu, H. Nakamura, M. Furuuchi et al., Limitation of cigarette consumption by CYP2A6*4,*7 and*9 polymorphisms, Eur Respir J 27 (2006), 289-292. (Pubitemid 43180904)
10. M. Fujieda, H. Yamazaki, T. Saito et al., Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobaccorelated lung cancer risk in male Japanese smokers, Carcinogenesis 25 (2004), 2451-2458. (Pubitemid 39625186)
11. D.F. Gu, L.J. Hinks, N.E. Morton and I.N. Day, The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit, Ann Hum Genet 64 (2000), 383-390. (Pubitemid 32055729)
12. F. Patterson, R.A. Schnoll, E.P.Wileyto et al., Toward personalized therapy for smoking cessation: a randomized placebocontrolled trial of bupropion, ClinPharmacol Ther 84 (2008), 320-325.
13. C. Lerman, R. Tyndale, F. Patterson et al., Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation, Clin Pharmacol Ther 79 (2006), 600-608. (Pubitemid 43817942)
14. R.A. Schnoll, F. Patterson, E.P. Wileyto, R.F. Tyndale, N. Benowitz and C. Lerman, Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: avalidation study, Pharmacol Biochem Behav 92 (2009), 6-11.
15. J. AudrainMcGovern, N. Al Koudsi, D. Rodriguez, E.P.Wileyto, P.G. Shields and R.F. Tyndale, The role of CYP2A6 in the emergence of nicotine dependence in adolescents, Pediatrics 119 (2007), 264-274.
16. G.A. Kyerematen and E.S. Vesell, Metabolism of nicotine, Drug Metab Rev 23 (1991), 3-41.
17. L.A. Peterson, A. Trevor and N. Castagnoli Jr., Stereochemical studies on the cytochrome P450 catalyzed oxidation of (S)nicotine to the (S)nicotine delta 1'(5')iminium species, J Med Chem 30 (1987), 249-54. (Pubitemid 17003794)
18. P.J. Murphy, Enzymatic oxidation of nicotine to nicotine 1'(5') iminium ion. A newly discovered intermediate in the metabolism of nicotine, J Biol Chem 248 (1973), 2796-2800.
19. J.W. Gorrod and A.R. Hibberd, The metabolism of nicotinedelta 1'(5')iminium ion, in vivo and in vitro, Eur J Drug Metab Pharmacokinet 7 (1982), 293-298. (Pubitemid 13185235)
20. S. Brandange and L. Lindblom, The enzyme "aldehyde oxidase" is an iminium oxidase. Reaction with nicotine delta 1'(5') iminium ion, Biochem Biophys Res Commun 91 (1979), 991-996. (Pubitemid 10145373)
21. N. Nakajima, T. Yamamoto, K. Nunoya et al., Role of human cytochrome P4502A6 in Coxidation of nicotine, Drug Metab Dispos 24 (1996), 1212-1217. (Pubitemid 26423061)
22. E.S. Messina, R.F. Tyndale and E.M. Sellers, A major role for CYP2A6 in nicotine Coxidation by human liver microsomes, J Pharmacol Exp Ther 282 (1997), 1608-1614. (Pubitemid 27408347)
23. K.E. Dicke, S.M. Skrlin and S.E. Murphy, Nicotine and 4( methylnitrosamino)1( 3pyridyl) butanone metabolism by cytochrome P450 2B6, DrugMetab Dispos 33 (2005), 1760-1764. (Pubitemid 41697258)
24. Z. Bao, X.X. He, X. Ding, S. Prabhu and J.Y. Hong, Metabolism of nicotine and cotinine by human cytoc P450 2A13, Drug Metab Dispos 33 (2005), 258-261. (Pubitemid 40216593)
25. S.E. Murphy, V. Raulinaitis and K.M. Brown, Nicotine 5'oxidation and methyl oxidation by P450 2A enzymes, Drug Metab Dispos 33 (2005), 1166-1173. (Pubitemid 41043760)
26. S. Koskela, J. Hakkola, J. Hukkanen et al., Expression of CYP2A genes in human liver and extrahepatic tissues, Biochem Pharmacol 57 (1999), 1407-1413. (Pubitemid 29225104)
27. T. Su, Z. Bao, Q.Y. Zhang, T.J. Smith, J.Y. Hong and X. Ding, Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobaccospecific carcinogen, 4( methylnitrosamino)1( 3pyridyl) 1butanone, Cancer Res 60 (2000), 5074-5079.
28. M. Nakajima, T. Yamamoto, K. Nunoya et al., Characterization of CYP2A6 involved in 3'hydroxylation of cotinine in human liver microsomes, J Pharmacol Exp Ther 277 (1996), 1010-1015.
29. D. Dempsey, P. Tutka, P. Jacob 3rd et al., Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity, Clin Pharmacol Ther 76 (2004), 64-72. (Pubitemid 38844735)
30. 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in largescale surveys of nicotine metabolic rate, J Anal Toxicol 30 (2006), 386-389. (Pubitemid 44274073)
31. N.L. Benowitz, P. Jacob 3rd, I. Fong and S. Gupta, Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine, J Pharmacol Exp Ther 268 (1994), 296-303. (Pubitemid 24039102)
32. O. Ghosheh and E.M. Hawes, Microsomal Nglucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation, Drug Metab Dispos 30 (2002), 1478-1483. (Pubitemid 35402058)
33. M. Nakajima, E. Tanaka, J.T. Kwon and T. Yokoi, Characterization of nicotine and cotinine Nglucuronidations in human liver microsomes, DrugMetab Dispos 30 (2002), 1484-1490. (Pubitemid 35397057)
34. O. Ghosheh and E.M. Hawes, Nglucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDPglucuronosyltransferases, Drug Metab Dispos 30 (2002), 991-996.
35. G.E. Kuehl and S.E. Murphy, Nglucuronidation of trans3' hydroxycotinine by human liver microsomes, Chem Res Toxicol 16 (2003), 1502-1506. (Pubitemid 38049368)
36. G.E. Kuehl and S.E. Murphy, Nglucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDPglucuronosyltransferases, Drug Metab Dispos 31 (2003), 1361-1368. (Pubitemid 37310325)
37. S. Kaivosaari, P. Toivonen, L.M. Hesse, M. Koskinen, M.H. Court and M. Finel, Nicotine glucuronidation and the human UDPglucuronosyltransferaseUGT2B10, MolPharmacol 72 (2007), 761-768.
38. J.Z. Berg, J. Mason, A.J. Boettcher, D.K. Hatsukami and S.E. Murphy, Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype, J Pharmacol Exp Ther 332 (2010), 202-209.
39. H. Yamanaka, M. Nakajima, M. Katoh et al., Trans3' hydroxycotinine Oand Nglucuronidations in human liver microsomes, Drug Metab Dispos 33 (2005), 23-30. (Pubitemid 40023510)
40. J.R. Cashman, S.B. Park, Z.C. Yang, S.A.Wrighton, P. Jacob 3rd and N.L. Benowitz, Metabolism of nicotine by human livermicrosomes: stereoselective formation of transnicotine N'oxide, Chem Res Toxicol 5 (1992), 639-646.
41. J.W. Gorrod and J. Wahren, Nicotine and related alkaloids: absorption, distribution, metabolism, excretion. London: Chapman and Hall, 1993.
42. H. Yamanaka, M. Nakajima, T. Fukami et al., CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions, Drug Metab Dispos 33 (2005), 1811-1818. (Pubitemid 41697266)
43. D. Dempsey, P. Jacob 3rd and N.L. Benowitz, Nicotine metabolism and elimination kinetics in newborns, Clin Pharmacol Ther 67 (2000), 458-465. (Pubitemid 30327484)
44. T. Tateishi, H. Nakura, M. Asoh et al., A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy, Life Sci 61 (1997), 2567-2574. (Pubitemid 28035581)
45. A. Parkinson, D.R. Mudra, C. Johnson, A. Dwyer and K.M. Carroll, The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes, Toxicol Appl Pharmacol 199 (2004), 193-209. (Pubitemid 39208721)
46. J.R. Baker, S. Satarug, P.E. Reilly et al., Relationships between nonoccupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples, Biochem Pharmacol 62 (2001), 713-721. (Pubitemid 32816988)
47. N. Al Koudsi, E.B. Hoffmann, A. Assadzadeh and R.F. Tyndale, Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors, Eur J Clin Pharmacol 66 (2010), 239-251.
48. S.G. Gourlay and N.L. Benowitz, The benefits of stopping smoking and the role of nicotine replacement therapy in older patients, Drugs Aging 9 (1996), 8-23. (Pubitemid 26235561)
49. T. Shimada, H. Yamazaki, M.Mimura, Y. Inui and F.P.Guengerich, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J Pharmacol Exp Ther 270 1994), 414-423. (Pubitemid 24229655)
50. M. Pasanen, Z. Rannala, A. Tooming, E.A. Sotaniemi, O. Pelkonen and A. Rautio, Hepatitis A impairs the function of human hepatic CYP2A6 in vivo, Toxicology 123 (1997), 177-184. (Pubitemid 27443389)
51. L. Molander, A. Hansson and E. Lunell, Pharmacokinetics of nicotine in healthy elderly people, Clin Pharmacol Ther 69 (2001), 57-65. (Pubitemid 32108672)
52. M.T. Kinirons and M.S. O'Mahony, Drug metabolism and ageing, Br J Clin Pharmacol 57 (2004), 540-544. (Pubitemid 38582172)
53. G.E. Swan, N.L. Benowitz, C.N. Lessov, P. Jacob 3rd, R.F. Tyndale and K. Wilhelmsen, Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence, Pharmacogenet Genomics 15 (2005), 115-125. (Pubitemid 40562988)
54. G.E. Swan, C.N. LessovSchlaggar, A.W. Bergen, Y. He, R.F. Tyndale and N.L. Benowitz, Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine, Pharmacogenet Genomics 19 (2009), 388-398.
55. S.M. Hoffman, D.R. Nelson and D.S. Keeney, Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19, Pharmacogenetics 11 (2001), 687-698. (Pubitemid 33078238)
56. N.L. Benowitz, C. Griffin and R. Tyndale, Deficient Coxidation of nicotine continued, Clin Pharmacol Ther 70 (2001), 567.
57. T. Fukami, M. Nakajima, E. Higashi, H. Yamanaka, H.L. McLeod and T. Yokoi, A novel CYP2A6*20 allele found in AfricanAmerican population produces a truncated protein lacking enzymatic activity, Biochem Pharmacol 70 (2005), 801-808. (Pubitemid 41058715)
58. T. Fukami, M. Nakajima, H. Yamanaka, Y. Fukushima, H.L. McLeod and T. Yokoi, A novel duplication type of CYP2A6 gene in AfricanAmerican population, Drug Metab Dispos 35 (2007), 515-520. (Pubitemid 46513277)
59. J.C. Mwenifumbo, N. Al Koudsi, M.K. Ho et al., Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent, Hum Mutat 29 (2008), 679-688. (Pubitemid 351614592)
60. C. Xu, Y.S. Rao, B. Xu et al., An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles, Biochem Biophys Res Commun 290 (2002), 318-324. (Pubitemid 34694502)
61. N. Al Koudsi, J.S. Ahluwalia, S.K. Lin, E.M. Sellers and R.F. Tyndale, A novel CYP2A6 allele (CYP2A6*35) resulting in an aminoacid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo, Pharmacogenomics J 9 (2009), 274-282.
62. S. Daigo, Y. Takahashi, M. Fujieda et al., A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur, Pharmacogenetics 12 (2002), 299-306. (Pubitemid 34620657)
63. T. Fukami, M. Nakajima, E. Higashi et al., Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity, DrugMetab Dispos 33 (2005), 1202-1210. (Pubitemid 41043764)
64. K. Kitagawa, N. Kunugita, M. Kitagawa and T. Kawamoto, CYP2A6*6, a novel polymorphismin cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity, J Biol Chem 276 (2001), 17830-17835.
65. M.Oscarson, R.A.McLellan, H.Gullsten et al., Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism, FEBS Lett 460 (1999), 321-327. (Pubitemid 29495962)
66. M. Oscarson, R.A. McLellan, V. Asp et al., Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity, Hum Mutat 20 (2002), 275-283.
67. R. Yoshida, M. Nakajima, K. Nishimura, S. Tokudome, J.T. Kwon and T. Yokoi, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro, Clin Pharmacol Ther 74 (2003), 69-76. (Pubitemid 36776178)
68. N.L. Benowitz, G.E. Swan, P. Jacob 3rd, C.N. LessovSchlaggar and R.F. Tyndale, CYP2A6 genotype and the metabolism and disposition kinetics of nicotine, Clin Pharmacol Ther 80 (2006), 457-467. (Pubitemid 44767882)
69. M. Haberl, B. Anwald, K. Klein et al., Three haplotypes associated with CYP2A6 phenotypes in Caucasians, Pharmacogenet Genomics 15 (2005), 609-624. (Pubitemid 41113334)
70. K.Kiyotani, M. Fujieda, H. Yamazaki et al., Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians, Drug Metab Pharmacokinet 17 (2002), 482-487.
71. Y. Rao, E. Hoffmann, M. Zia et al., Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking, Mol Pharmacol 58 (2000), 747-755.
72. J. Wang, M. Pitarque and M. IngelmanSundberg, 3'UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression, Biochem Biophys Res Commun 340 (2006), 491-497. (Pubitemid 43021775)
73. J.C. Mwenifumbo, C.N. LessovSchlaggar, Q. Zhou et al., Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism, Clin Pharmacol Ther 83 (2008), 115-121.
74. M.K. Ho, J.C. Mwenifumbo, N. Al Koudsi et al., Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in AfricanAmerican light smokers, Clin Pharmacol Ther 85 (2009), 635-643.
75. R.Yoshida,M.Nakajima,Watanabe, J.T.Kwon and T.Yokoi, Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism, Br J Clin Pharmacol 54 (2002), 511-517. (Pubitemid 35356877)
76. M.Nakajima, T. Fukami,H.Yamanaka et al., Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations, Clin Pharmacol Ther 80 (2006), 282-297. (Pubitemid 44313906)
77. M.K. Ho, J.C. Mwenifumbo, B. Zhao, E.M. Gillam and R.F. Tyndale, A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of BlackAfrican descent, Pharmacogenet Genomics 18 (2008), 67-75. (Pubitemid 351161649)
78. N. Al Koudsi, J.C. Mwenifumbo, E.M. Sellers, N.L. Benowitz, G.E. Swan and R.F. Tyndale, Characterization of the novel CYP2A*21 allele using in vivo nicotine kinetics, Eur J Clin Pharmacol 62 (2006), 481-484. (Pubitemid 43873720)
79. K. Kitagawa, N. Kunugita, T. Katoh, M. Yang and T. Kawamoto, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCRRFLP, Biochem Biophys Res Commun 262 (1999), 146-151. (Pubitemid 29412638)
80. X. Zhang, K. Ameno, S. Ameno et al., Effects of whole deletion of CYP2A6 on nicotine metabolism in humans, Drug Chem Toxicol 25 (2002), 203-213. (Pubitemid 34475650)
81. H. Yamanaka, M. Nakajima, K. Nishimura et al., Metabolic profile of nicotine in subjectswhoseCYP2A6 gene is deleted, Eur J Pharm Sci 22 (2004), 419-425. (Pubitemid 38953900)
82. M. Yang, N. Kunugita, K. Kitagawa et al., Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphismof drugmetabolizing enzymes, Cancer Epidemiol Biomarkers Prev 10 (2001), 589-593. (Pubitemid 32703192)
83. G.D. Byrd, K.M. Chang, J.M. Greene and J.D. deBethizy, Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans3' hydroxycotinine in smokers, Drug Metab Dispos 20 (1992), 192-197.
84. M. Nakajima, S. Yamagishi, H. Yamamoto, T. Yamamoto, Y. Kuroiwa and T. Yokoi, Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans, Clin Pharmacol Ther 67 (2000), 57-69. (Pubitemid 30078388)
85. N.L. Benowitz, E.J. PerezStable, B. Herrera and P. Jacob 3rd., Slower metabolism and reduced intake of nicotine from cigarette smoking in ChineseAmericans, J Natl Cancer Inst 94 (2002), 108-115. (Pubitemid 34121290)
86. E.T. Moolchan, F.H. Franken and M. JaszynaGasior, Adolescent nicotine metabolism: ethnoracial differences among dependent smokers, Ethn Dis 16 (2006), 239-243. (Pubitemid 46959274)
87. D.B. Kandel, M.C. Hu, C. Schaffran, J.R. Udry and N.L. Benowitz, Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults, Am J Epidemiol 165 (2007), 901-910. (Pubitemid 46536667)
88. J.C. Mwenifumbo and R.F. Tyndale, Molecular genetics of nicotine metabolism, Handb Exp Pharmacol 192 (2009), 235-259.
89. N.L. Benowitz, C.N. LessovSchlaggar, G.E. Swan and P. Jacob 3rd, Female sex and oral contraceptive use accelerate nicotine metabolism, Clin Pharmacol Ther 79 (2006), 480-488.
90. E. Johnstone, N. Benowitz, A. Cargill et al., Determinants of the rate of nicotine metabolism and effects on smoking behavior, Clin Pharmacol Ther 80 (2006), 319-330. (Pubitemid 44479751)
91. I. Berlin, M.J. Gasior and E.T. Moolchan, Sexbased and hormonal contraception effects on themetabolism of nicotine among adolescent tobaccodependent smokers, Nicotine Tob Res 9 (2007), 493-498. (Pubitemid 46534461)
92. H.Yamazaki, K. Inoue,M.Hashimoto and T. Shimada, Roles of CYP2A6 and CYP2B6 in nicotine Coxidation by human liver microsomes, Arch Toxicol 73 (1999), 65-70. (Pubitemid 29226163)
93. N. Al Koudsi and R.F. Tyndale, Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism, Xenobiotica 40 (2010), 381-392.
94. U.M. Zanger, K. Klein, T. Saussele, J. Blievernicht, M.H. Hofmann and M. Schwab, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance, Pharmacogenomics 8 (2007), 743-759. (Pubitemid 47288975)
95. S.L.Mo, Y.H. Liu,W. Duan,M.Q.Wei, J.R. Kanwar and S.F. Zhou, Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6, Curr Drug Metab 10 (2009), 730-753.
96. H.Z. Ring, A.M. Valdes, D.M. Nishita et al., Genegene interactions between CYP2B6 and CYP2A6 in nicotine metabolism, Pharmacogenet Genomics 17 (2007), 1007-1015. (Pubitemid 351339485)
97. A.M. Lee, C. Jepson, P.G. Shields, N. Benowitz, C. Lerman and R.F. Tyndale, CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy, Cancer Epidemiol Biomarkers Prev 16(2007), 1312-1314. (Pubitemid 46984979)
98. E. Garattini, M. Fratelli and M. Terao, Mammalian aldehyde oxidases: genetics, evolution and biochemistry, CellMol Life Sci 65 (2008), 1019-1048.
99. E. Garattini, R. Mendel, M.J. Rom̃ao, R. Wright and M. Terao, Mammalian molybdoflavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology, Biochem J 372 (2003), 15-32. (Pubitemid 36609603)
100. G. Chen, A.S. BlevinsPrimeau, R.W. Dellinger, J.E.Muscat and P. Lazarus, Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp > Tyr) polymorphism, Cancer Res 67 (2007), 9024-9029. (Pubitemid 47535885)
101. P.I.Mackenzie, K.W. Bock, B. Burchell et al., Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily, PharmacogenetGenomics 15 (2005), 677-685. (Pubitemid 41345319)
102. N.L. Benowitz, E.J. PerezStable, I. Fong, G.Modin, B. Herrera and P. Jacob 3rd, Ethnic differences inNglucuronidation of nicotine and cotinine, J Pharmacol Exp Ther 291 (1999), 1196-1203.
103. G. Chen, R.W. Dellinger, C.J. Gallagher, D. Sun and P. Lazarus, Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobaccospecific nitrosamines, Pharmacogenet Genomics 18 (2008), 181-191. (Pubitemid 351323232)
104. S.K. Krueger and D.E. Williams, Mammalian flavincontaining monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism, Pharmacol Ther 106 (2005), 357-387. (Pubitemid 40726294)
105. D. Hernandez, A. Janmohamed, P. Chandan, I.R. Phillips and E.A. Shephard, Organization and evolution of the flavincontaining monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters, Pharmacogenetics 14 (2004), 117-130. (Pubitemid 38253647)
106. N.L. Benowitz and P. Jacob 3rd, Trans3' hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking, Br J Clin Pharmacol 51 (2001), 53-59. (Pubitemid 32118820)
107. D.K. Hatsukami, M. Grillo, P.R. Pentel, C. Oncken and R. Bliss, Safety of cotinine in humans: physiologic, subjective, and cognitive effects, Pharmacol Biochem Behav 57 (1997), 643-650. (Pubitemid 27334410)
108. D. Hatsukami, B. Lexau, D. Nelson, P.R. Pentel, M. Sofuoglu and A. Goldman, Effects of cotinine on cigarette selfadministration, Psychopharmacology (Berl) 138 (1998), 184-189.
109. N.L. Benowitz, F. Kuyt, P. Jacob 3rd, R.T. Jones and A.L. Osman, Cotinine disposition and effects, Clin Pharmacol Ther 34 (1983), 604-611. (Pubitemid 14247719)
110. M.D. Li, R. Cheng, J.Z.Ma and G.E. Swen, A metaanalysis of estimated genetic and environmental effects on smoking behavior inmale and female adult twins, Addiction 98 (2003), 23-31. (Pubitemid 36044333)
111. J.R. Koopmans, W.S. Slutske, A.C. Heath, M.C. Neale and D.I. Boomsma, The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins, Behav Genet 29 (1999), 383-393. (Pubitemid 30368316)
112. J.Y. Khokhar, C.S. Ferguson, A.Z. Zhu and R.F. Tyndale, Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment, Annu Rev Pharmacol Toxicol 50 (2010), 39-61.
113. K. Iwahashi, C. Waga and T. Takimoto, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior, Neuropsychobiology 49 (2004), 101-104. (Pubitemid 38253136)
114. A.A. Strasser, V.Malaiyandi, E. Hoffmann, R.F. Tyndale and C. Lerman, An association of CYP2A6 genotype and smoking topography, Nicotine Tob Res 9 (2007), 511-518. (Pubitemid 46534464)
115. C. Lerman, C. Jepson, E.P. Wileyto et al., Genetic variation in nicotine metabolism predicts the efficacy of extendedduration transdermal nicotine therapy, Clin Pharmacol Ther 87 (2010), 553-557.
116. M. Munafò, T. Clark, E. Johnstone, M. Murphy and R. Walton, The genetic basis for smoking behavior: a systematic review and metaanalysis, Nicotine Tob Res 6 (2004), 583-597. (Pubitemid 39248145)
117. S. Huang, D.G. Cook, L.J. Hinks et al., CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behavior and cotinine levels in 1518 UK adolescents, Pharmacogenet Genomics 15 (2005), 839-850. (Pubitemid 41666766)
118. J. O'Loughlin, J. DiFranza, J. Tarasuk et al., Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicators, Tob Control 11 (2002), 354-360.
119. A.V. Prokhorov, U.E. Pallonen, J.L. Fava, L. Ding and R. Niaura, Measuring nicotine dependence among highrisk adolescent smokers, Addict Behav 21 (1996), 117-127. (Pubitemid 26080749)
120. J. Audrain, K.P. Tercyak, P. Goldman and A. Bush, Recruiting adolescents into genetic studies of smoking behavior, Cancer Epidemiol Biomarkers Prev 11 (2002), 249-252. (Pubitemid 34327001)
121. U. Broms, K. Silventoinen, P.A. Madden, A.C. Heath and J. Kaprio, Genetic architecture of smoking behavior: a study of Finnish adult twins, Twin Res Hum Genet 9 (2006), 64-72. (Pubitemid 43384794)
122. J.R. Koopmans, L.J. van Doornen and D.I. Boomsma, Association between alcohol use and smoking in adolescent and young adult twins: a bivariate genetic analysis, Alcohol Clin Exp Res 21 (1997), 537-546. (Pubitemid 27217199)
123. M.D. Li, The genetics of nicotine dependence, Curr Psychiatry Rep 8 (2006), 158-164.
124. J.M. Vink, G. Willemsen and D.I. Boomsma, Heritability of smoking initiation and nicotine dependence, Behav Genet 35 (2005), 397-406. (Pubitemid 40848169)
125. H.H. Maes, P.F. Sullivan, C.M. Bulik et al., A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence, Psychol Med 34 (2004), 1251-1261. (Pubitemid 39517155)
126. P.F. Sullivan and K.S. Kendler, The genetic epidemiology of smoking, Nicotine Tob Res 1 (1999), 51-57.
127. L.E.O'Dell, A psychobiological framework of the substrates that mediate nicotine use during adolescence, Neuropharmacology 56 (2009), 263-278.
128. W.Adriani, O.Granstrem, S.Macri, G. Izykenova, S.Dambinova and G. Laviola, Behavioral and neurochemical vulnerability during adolescence in mice: studies with nicotine, Neuropsychopharmacology 29 (2004), 869-878. (Pubitemid 38526787)
129. P.J. Diggle, K.Y. Liang and S.L. Zeger, Analysis of Longitudinal data. New York: Oxford Press, 1994.